J&J Partnership, page-362

....and yet another small brick in the foundations of OCC's pathway to commercialisation.

Looks like autologous Mesenchymal stem-cells derived from patients own fat cells, but another trial that has been granted the green flag by the FDA. This is a great backdrop for Orthocell.

JNJ know OCC has a superior treatment for tendons (using tenocytes) which its just reported great results in. They also know OCC's treatment of osteoarthritis with collagen stem cells (chondrocytes) is biologically superior in the regeneration of cartilage tissue. OCC (and J&J) must be salivating that the FDA is okaying the trial of autologous stem cells with increasing frequency (MS recently as well). They have the superior treatments for tendons and cartilage - though nothing wrong with a little Mesenchymal/Chondrocyte mix in the latter - and the pathway to a confirmatory trial in the USA under the FDA's guidance, as the company has reported, is wide open:

https://www.midwestmedicaledition.com/2021/12/10/377893/sanford-health-opens-groundbreaking-stem-cell-trial-for-patients-with-osteoarthritis

Paul must be scratching his head at the share price. Not ideal communication again in what should have been a blow them away trial. Investors need him to connect the dots a little better for them.